{"id":"intralesional-propranolol-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, edema)"},{"rate":null,"effect":"Transient hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1671","moleculeType":"Small molecule","molecularWeight":"295.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Propranolol, a non-selective beta-blocker, when injected directly into hemangioma lesions, inhibits beta-adrenergic signaling that promotes endothelial cell proliferation and survival. This leads to decreased expression of pro-angiogenic factors like VEGF and FGF, resulting in apoptosis of hemangioma cells and gradual involution of the vascular lesion. The local injection approach delivers high drug concentrations directly to the target tissue while minimizing systemic exposure.","oneSentence":"Intralesional propranolol injection blocks beta-adrenergic receptors within hemangioma tissue, reducing angiogenesis and promoting vascular regression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:31.568Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infantile hemangioma (intralesional injection)"},{"name":"Proliferating hemangiomas"}]},"trialDetails":[{"nctId":"NCT07104526","phase":"NA","title":"Low-Dose Propranolol and Bleomycin for Infantile Hemangioma (IH)","status":"COMPLETED","sponsor":"Wuhan Integrated Traditional Chinese and Western Medicine Hospital","startDate":"2024-01-01","conditions":"Infantile Hemangioma (IH)","enrollment":260},{"nctId":"NCT04288700","phase":"PHASE4","title":"Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-10-01","conditions":"Infantile Hemangioma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"intralesional propranolol injection","genericName":"intralesional propranolol injection","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intralesional propranolol injection blocks beta-adrenergic receptors within hemangioma tissue, reducing angiogenesis and promoting vascular regression. Used for Infantile hemangioma (intralesional injection), Proliferating hemangiomas.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}